Features of cellular structure of the induced sputum and profile of cytokines at sintropiya of bronchial asthma and obesity at young patients


Cite item

Full Text

Abstract

Aim. To estimate changes of cellular structure of the induced sputum at young patients with bronchial asthma at interrelations with BMI and level of cytokines in blood plasma. Materials and methods. 164 patients with bronchial asthma were divided into 2 groups taking into BMI: the 1st group included patients with bronchial asthma and BMI from 18 to 25 kg/m2, patients with bronchial asthma and BMI from 30 to 40 kg/m2 entered into the 2nd group. The group of control was made by 40 almost healthy volunteers. Estimated existence of excess weight and defined obesity degree according to recommendations of World Health Organization. Studied the level of control of bronchial asthma, cellular structure of the induced sputum, the IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-15, IL-17, TNF-α, INF-γ levels in plasma of peripheral blood. Results. There are presented the results of the research of cellular profile of the induced sputum and profile of cytokines at patients with bronchial asthma depending on BMI and severity of the disease. The received results testify to prevalence of eosinophilic type of an inflammation in the group of patients with BMI less than 25 kg/m2 whereas at patients mainly paucigranulation inflammation decided on obesity. The highest content of the Il-17 was registered at patients with bronchial asthma and obesity as in comparison with indicators of patients with normal BMI, and with almost healthy that, perhaps, is the reason of low effect of steroid therapy at these patients. Conclusion. Endotype assessment before basic antiinflammatory therapy at patients with the first time diagnosed bronchial asthma, will be able to help with selection of the most optimum treatment to each specific patient.

About the authors

I A Soloveva

Krasnoyarsk state medical university named after prof. V.F. Voino-Yasenetsky; Regional Clinical Hospital

Email: solovieva.irina@inbox.ru
к.м.н., доцент каф. внутренних болезней №2 с курсом ПО, врач-аллерголог Краевого ГБУЗ «Краевая клиническая больница» Krasnoyarsk, Russia

E A Sobko

Krasnoyarsk state medical university named after prof. V.F. Voino-Yasenetsky; Regional Clinical Hospital

м.н., доцент каф. внутренних болезней №2 с курсом ПО; зав. отд-нием аллергологии Krasnoyarsk, Russia

I V Demko

Krasnoyarsk state medical university named after prof. V.F. Voino-Yasenetsky; Regional Clinical Hospital

д.м.н., проф., зав. каф. внутренних болезней №2 с курсом ПО Krasnoyarsk, Russia

A Yu Kraposhina

Krasnoyarsk state medical university named after prof. V.F. Voino-Yasenetsky

к.м.н., доцент каф. внутренних болезней №2 с курсом ПО Krasnoyarsk, Russia

M M Loktionova

Krasnoyarsk state medical university named after prof. V.F. Voino-Yasenetsky

клин. ординатор каф. внутренних болезней №2 с курсом ПО Krasnoyarsk, Russia

N V Gordeeva

Krasnoyarsk state medical university named after prof. V.F. Voino-Yasenetsky; Regional Clinical Hospital

к.м.н., доцент каф. внутренних болезней №2 с курсом ПО; врач-пульмонолог Краевого ГБУЗ «Краевая клиническая больница» Krasnoyarsk, Russia

References

  1. World Health Organization. Obesity and Overweight. Fact Sheet No 311; http://www.who.int/mediacentre/factsheets/fs311/en/index.html Date last accessed: May 5, 2011.
  2. Telenga E.D, Tideman S.W, Kerstjens H.A.M, ten Hacken N.H.T, Timens W, Postma D.S, van den Berge M. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012; 67(8): 1060-1068.
  3. Beuther D.A, Sutherland E.R. Overweight, obesity, and incident asthma: A meta - analysis of prospective epidemiologic studies. Am J Respir Crit Care Med. 2007; 175: 661-666. doi: 10.1164/rccm.200611-1717OC
  4. Camargo C.A. Jr, Boulet L.P, Sutherland E.R, Busse W.W, Yancey S.W, Emmett A.H, Ortega H.G, Ferro T.J. Body mass index and response to asthma therapy: Fluticasone propionate/salmeterol versus montelukast. J Asthma. 2010; 47: 76-82.
  5. Saint-Pierre P, Bourdin A, Chanez P, Daures J.P, Godard P. Are overweight asthmatics more difficult to control? Allergy. 2006;61:79-84. doi: 10.1111/j.1398-9995.2005.00953.x
  6. Sutherland T.J.T, Cowan J.O, Young S, Goulding A, Grant A.M, Williamson A, Brassett K, Herbison G.P, Taylor D.R. The association between obesity and asthma interactions between systemic and airway Inflammation. All AJRCCM. 2008; 178 (5).
  7. Bousquet J, Chanez P, Lacoste J.Y, Barnéon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P. Eosinophilic inflammation in asthma. N Engl J Med. 1990; 323: 1033-1039. doi: 10.1056/NEJM199010113231505
  8. Fahy J.V, Kim K.W, Liu J, Boushey H.A. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995; 95: 843-52.
  9. Turner M.O, Hussack P, Sears M.R, Dolovich J, Hargreave F.E. Exacerbations of asthma without sputum eosinophilia. Thorax. 1995; 50: 1057-1061.
  10. Douwes J, Gibson P, Pekkanen J, Pearce N. Non - eosinophilic asthma: importance and possible mechanisms. Thorax. 2002; 57: 643-648.
  11. Kay A.B, Phipps S, Robinson D.S. The role for eosinophils in airway remodeling in asthma. Tends Immunol. 2004; 25: 477-482. doi: 10.1016/j.it.2004.07.006
  12. Reuter S, Heinz A, Sieren M, Wiewrodt R, Gelfand E.W, Stassen M, Buhl R, Taube C. Mast cell - derived tumor necrosis factor is essential for allergic airway disease. Eur Respir J. 2008; 31: 773-782. doi: 10.1183/09031936.00058907
  13. Douwes J, Gibson P, Pekkanen J, Pearce N. Non - eosinophilic asthma: importance and possible mechanisms. Thorax. 2002; 57: 643-648.
  14. Leckie M.J, Brinke A, Khan J, Diamant Z, O'Connor B.J, Walls C.M, Mathur A.K, Cowley H.C, Chung K.F, Djukanovic R, Hansel T.T, Holgate S.T, Sterk P.J, Barnes P.J. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper - responsiveness, and the late asthmatic response. Lancet. 2000; 356: 2144-2148.
  15. Bryan S.A, O’Connor B.J, Matti S, Leckie M.J, Kanabar V, Khan J, Warrington S.J, Renzetti L, Rames A, Bock J.A, Boyce M.J, Hansel T.T, Holgate S.T, Barneset P.J. Effects of recombinant human interleukin-12 on eosinophils, airway hyper - responsiveness, and the late asthmatic response. Lancet. 2000; 356: 2149-2153.
  16. Kips J.C, O’Connor B.J, Langley S.J, Woodcock A, Kerstjens H.A, Postma D.S, Danzig M, Cuss F, Pauwels R.A. Effect of SCH55700, a humanised anti - human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003; 167: 1655-1659. doi: 10.1164/rccm.200206-525OC
  17. Wilson R.H, Whitehead G.S, Nakano H, Free M.E, Kolls J.K, Cook D.N. Allergic sensitization through the airway primed Th17- dependent neutrophilia and airway hyperresponsiveness. Am J Respir Cm Crit Care. 2009; 180: 720-730.
  18. Stern J.S, Hirsch J, Blair S.N, Foreyt J.P, Frank A, Kumanyika S.K, Madans J.H, Marlatt G.A, St Jeor S.T, Stunkard A.J. Weighing the options: criteria for evaluating weight - management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res. 1995; 3 (6): 591-604.
  19. Rio-Navarro В, Cisneros-Rivero M, Berber-Eslava A, Espínola-Reyna G, Sienra-Monge J. Exercise induced bronchospasm in asthmatic and non - asthmatic obese children. Allergol Immunopathol (Madr). 2000; 28 (1): 5-11.
  20. Shore S.A. Obesity and asthma: location, location, location. Eur Respir J. 2013; 41 (2): 253-254. doi: 10.1183/09031936.00128812
  21. Авдеев С.Н., Анаев Э.Х., Чучалин А.Г. Применение метода индуцированной мокроты для оценки интенсивности воспаления дыхательных путей. Пульмонология. 1998; 2: 81-85.
  22. Kips J.C, Fahy J.V, Hargreave F.E. Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma. Eur Respir J. 2008; 11: 9-12.
  23. Simpson J.L, Scott R, Boyle M.J, Gibson P.G. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006; 11:54-61.
  24. Ненашева Н.М. Современное представление о фенотипах бронхиальной астмы. Фарматека. 2013; 4: 257.
  25. Newton R, Leigh R, Glembycz M. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung disease. Prarmacology and Therapeutics. 2010;125:286-327.
  26. Трофимов В., Миронова Ж. Терапевтически резистентная астма. Врач. 2012;3:2-4.
  27. Федосеев Г.Б., Трофимов В.И., Рогачева Н.Н., Разумовская Т.С. Роль нейтрофилов и бактериальной инфекции респираторного тракта у больных бронхиальной астмой и хронической обструктивной болезнью легких. Росс. аллергологический журн. 2011; 2: 34-43.
  28. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol. 1995; 154: 4719-4725.
  29. Shin B, Kwon H.S, Park S.Y, Kim T.B, Moon H.B, Cho Y.S. The transition of sputum inflammatory cell profiles is variable in stable asthma patients. Asia Pac Allergy. 2017; 7 (1): 19-28. doi: 10.5415/apallergy.2017.7.1.19
  30. Cowan D.C, Cowan J.O, Palmay R, Williamson A, Taylor D.R. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax. 2010; 65: 384-390.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies